全文获取类型
收费全文 | 20575篇 |
免费 | 1649篇 |
国内免费 | 263篇 |
专业分类
耳鼻咽喉 | 65篇 |
儿科学 | 508篇 |
妇产科学 | 395篇 |
基础医学 | 994篇 |
口腔科学 | 763篇 |
临床医学 | 2913篇 |
内科学 | 3905篇 |
皮肤病学 | 435篇 |
神经病学 | 805篇 |
特种医学 | 506篇 |
外科学 | 1228篇 |
综合类 | 1986篇 |
现状与发展 | 6篇 |
预防医学 | 4740篇 |
眼科学 | 299篇 |
药学 | 1460篇 |
19篇 | |
中国医学 | 622篇 |
肿瘤学 | 838篇 |
出版年
2024年 | 51篇 |
2023年 | 395篇 |
2022年 | 636篇 |
2021年 | 986篇 |
2020年 | 1194篇 |
2019年 | 887篇 |
2018年 | 882篇 |
2017年 | 774篇 |
2016年 | 790篇 |
2015年 | 686篇 |
2014年 | 1323篇 |
2013年 | 2058篇 |
2012年 | 1014篇 |
2011年 | 1170篇 |
2010年 | 1001篇 |
2009年 | 917篇 |
2008年 | 922篇 |
2007年 | 938篇 |
2006年 | 917篇 |
2005年 | 748篇 |
2004年 | 622篇 |
2003年 | 553篇 |
2002年 | 497篇 |
2001年 | 384篇 |
2000年 | 285篇 |
1999年 | 286篇 |
1998年 | 242篇 |
1997年 | 177篇 |
1996年 | 210篇 |
1995年 | 145篇 |
1994年 | 99篇 |
1993年 | 114篇 |
1992年 | 83篇 |
1991年 | 62篇 |
1990年 | 59篇 |
1989年 | 55篇 |
1988年 | 67篇 |
1987年 | 44篇 |
1986年 | 36篇 |
1985年 | 32篇 |
1984年 | 30篇 |
1983年 | 22篇 |
1982年 | 17篇 |
1981年 | 24篇 |
1980年 | 14篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1976年 | 8篇 |
1975年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
25.
26.
Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most effective option and the gold standard for ovarian cancer (OC) risk-reduction, particularly given the absence of an effective national OC screening programme. However, premenopausal RRSO leads to premature surgical menopause with detrimental long-term health sequelae particularly in women who do not/are unable to take hormone replacement therapy (HRT). HRT uptake in women undergoing pre-menopausal oophorectomy appears low and is dependent on informed counselling, the safety of HRT and efficacy in mitigating the health sequelae of premature menopause. Acceptance of a central role for the fallopian tube in OC etiopathogenesis, coupled with the detrimental consequences of premature menopause, has led to the attractive proposal of early-salpingectomy with delayed oophorectomy as an alternative OC surgical prevention strategy in premenopausal women who have completed childbearing but decline or wish to delay RRSO. The successful implementation of risk reducing surgery for OC prevention depends on the acceptability of surgery to both, recipients (e.g. BRCA1/BRCA2 carriers) and intervention deliverers (healthcare professionals/researchers). Acceptability is also informed by an understanding of health outcomes following risk reducing surgery and the safety of HRT. It is therefore vital to understand the effects of surgery on important health outcomes such as cardiovascular health, neurological function and bone health. We present a comprehensive review of acceptability, the selected health outcomes mentioned above and HRT safety following risk reducing surgery. 相似文献
27.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
28.
29.
剖宫产术后并发下肢静脉栓塞的护理及预防 总被引:1,自引:0,他引:1
王茜 《安徽卫生职业技术学院学报》2006,5(1):87-87,85
通过对20例剖宫产术后并发下肢静脉栓塞病人的观察,分析了发生静脉栓塞的原因,提出了相应的护理、观察、预防等一系列措施. 相似文献
30.
Eric W. Dickson MD Gary V. Doern PhD Leo Trevino PhD Michelle Mazzoni PhD Stephen O. Heard MD 《Academic emergency medicine》2003,10(10):1019-1023
OBJECTIVES: Patients undergoing emergent endotracheal intubation are at increased risk for developing pneumonia. Although numerous strategies have been investigated to reduce ventilator-associated pneumonia (VAP), the incidence of VAP and its associated mortality remains high. This investigation tested the hypothesis that LiquiVent (Alliance Pharmaceutical, San Diego, CA-LV) delivered antibiotics (via spray-dried microspheres-SDM) would improve survival in a rat model of descending gram-negative pneumonia. METHODS: Wistar rats (n = 49) were randomized to receive prophylaxis with 1). nothing (controls); 2). intramuscular (IM) tobramycin, 3). intratracheal LV plus SDM shells (vehicle), 4). intratracheal LV plus SDM shells plus IM tobramycin, or 5). intratracheal LV plus SDM containing 1 mg/kg of tobramycin. All interventions were given 24 hours before a bacterial challenge with 10(8) colony-forming units of intratracheal Klebsiella pneumoniae. Mortality at ten days was the sole outcome measure. Survival in individual groups was compared with controls by Fisher's exact test with Bonferroni correction for multiple comparisons. RESULTS: All animals in the control group died of pneumonia within ten days of bacterial inoculation (0% survival). Prophylaxis with either IM tobramycin or SDM vehicle plus IM tobramycin provided no protection (0% survival). This is in sharp contrast to the cohort receiving pretreatment with tobramycin-containing SDM delivered via LV, in which 60% of the animals survived to study completion (p < 0.05). CONCLUSIONS: Prophylaxis with SDM containing antibiotics delivered in low-dose LV provided significant protection in a rat model of descending gram-negative pneumonia. These data support the hypothesis that perfluorocarbon-delivered intratracheal antimicrobials may be useful in the prevention of VAP. 相似文献